Feasibility and Safety of IL-15-Activated CD56+ Cell Therapy in High-Risk Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation: Phase I Clinical Trial.
We identified a feasible method to activate CD56<sup>+</sup> cells and evaluate the safety of their infusion in patients. Despite the value of activating CD56<sup>+</sup> cells with IL-15, further studies with larger sample sizes are needed to confirm and validate the current hypothesi (registration number: IRCT20230801058996N2).
Authors
- Mozhdeh Mohammadian (ORCID: https://orcid.org/0000-0003-4957-8797)
- Sahar Parkhideh (ORCID: https://orcid.org/0000-0001-7846-3222)
- Amirhossein Izadpanah (ORCID: https://orcid.org/0000-0001-9852-1821)
- Mehrshad Seresht-Ahmadi
- Elham Roshandel
- Ahmad Gharehbaghian
- Shiva Eskandarian
- Mehdi Bakhtiyaridovvmbaygi
- Abbas Hajifathali
Institutions
- Shahid Beheshti University (IR)
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- PubMed
- Published
- 2026-02-14
- DOI
- https://doi.org/10.22074/cellj.2025.2057631.1827
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 24.43